GlassScriptPhysician profile
Harpreet Reeba
NPI 1104268796
$4,842.77
in general payments reported to CMS, 2019-2025
20 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $192 · 2021: $797 · 2022: $340 · 2023: $660 · 2024: $1,170 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $639.74 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $627.18 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $583.64 | 2019-2025 | Invega, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $297.95 | 2025 | Cobenfy |
| Lundbeck LLC | $288.58 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $258.00 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $220.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.11 | 2020-2025 | Trintellix |
| Axsome Therapeutics, INC. | $99.60 | 2022-2025 | Auvelity |
| Alkermes, INC. | $92.40 | 2019-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.05 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $40.11 | 2021-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $35.34 | 2025 | Jornay Pm |
| Allergan, INC. | $34.14 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $34.14 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $28.25 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $15.42 | 2023 | Gralise |
| Eisai INC. | $15.01 | 2020 | |
| Shire North American Group INC | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpreet Reeba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.